51.41
-1.95(-3.65%)
Currency In USD
| Previous Close | 53.36 |
| Open | 52.88 |
| Day High | 53.76 |
| Day Low | 51.12 |
| 52-Week High | 58.4 |
| 52-Week Low | 21.02 |
| Volume | 1.31M |
| Average Volume | 1.69M |
| Market Cap | 4.1B |
| PE | -13.71 |
| EPS | -3.75 |
| Moving Average 50 Days | 47.38 |
| Moving Average 200 Days | 38.42 |
| Change | -1.95 |
If you invested $1000 in Akero Therapeutics, Inc. (AKRO) since IPO date, it would be worth $2,807.31 as of July 01, 2025 at a share price of $51.43. Whereas If you bought $1000 worth of Akero Therapeutics, Inc. (AKRO) shares 5 years ago, it would be worth $1,541.2 as of July 01, 2025 at a share price of $51.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need,
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, t
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
GlobeNewswire Inc.
May 10, 2025 2:00 PM GMT
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUT